Hideki Ohnota

601 total citations
26 papers, 509 citations indexed

About

Hideki Ohnota is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Hideki Ohnota has authored 26 papers receiving a total of 509 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 8 papers in Endocrinology, Diabetes and Metabolism and 7 papers in Surgery. Recurrent topics in Hideki Ohnota's work include Pancreatic function and diabetes (6 papers), Metabolism, Diabetes, and Cancer (5 papers) and Quinazolinone synthesis and applications (4 papers). Hideki Ohnota is often cited by papers focused on Pancreatic function and diabetes (6 papers), Metabolism, Diabetes, and Cancer (5 papers) and Quinazolinone synthesis and applications (4 papers). Hideki Ohnota collaborates with scholars based in Japan and United States. Hideki Ohnota's co-authors include Harunobu Mukaiyama, Miho Kobayashi, Takashi Koizumi, Ryuzo Sasaki, Shin-ichi Yanagawa, Hideo Chiba, F. Sato, Masayuki Isaji, Keiko Misawa and Hiroaki Kobayashi and has published in prestigious journals such as Journal of Biological Chemistry, Scientific Reports and Biochemical and Biophysical Research Communications.

In The Last Decade

Hideki Ohnota

26 papers receiving 488 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hideki Ohnota Japan 16 189 116 115 91 70 26 509
Osamu Asano Japan 12 215 1.1× 152 1.3× 99 0.9× 86 0.9× 11 0.2× 36 652
Nahed K. Ahmed United States 13 272 1.4× 29 0.3× 47 0.4× 31 0.3× 60 0.9× 30 533
J. C. Mani France 11 198 1.0× 69 0.6× 30 0.3× 26 0.3× 25 0.4× 18 441
Van N. Michalek United States 11 338 1.8× 23 0.2× 33 0.3× 127 1.4× 50 0.7× 20 598
Naonori Inoue Japan 14 205 1.1× 24 0.2× 53 0.5× 178 2.0× 24 0.3× 47 546
Katsuhiro Kawakami Japan 16 170 0.9× 203 1.8× 15 0.1× 133 1.5× 58 0.8× 43 631
Paola Finotti Italy 14 412 2.2× 14 0.1× 81 0.7× 71 0.8× 37 0.5× 39 670
Katharina R. Beck Switzerland 15 185 1.0× 44 0.4× 126 1.1× 63 0.7× 7 0.1× 22 539
Stephen Eisennagel United States 8 266 1.4× 97 0.8× 42 0.4× 16 0.2× 31 0.4× 12 480
Mark Hilliard Ireland 13 475 2.5× 96 0.8× 32 0.3× 50 0.5× 15 0.2× 15 794

Countries citing papers authored by Hideki Ohnota

Since Specialization
Citations

This map shows the geographic impact of Hideki Ohnota's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideki Ohnota with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideki Ohnota more than expected).

Fields of papers citing papers by Hideki Ohnota

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hideki Ohnota. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideki Ohnota. The network helps show where Hideki Ohnota may publish in the future.

Co-authorship network of co-authors of Hideki Ohnota

This figure shows the co-authorship network connecting the top 25 collaborators of Hideki Ohnota. A scholar is included among the top collaborators of Hideki Ohnota based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hideki Ohnota. Hideki Ohnota is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hasegawa, Aiko, Shoji Saito, Shigeru Nakano, et al.. (2021). Mutated GM‐CSF‐based CAR‐T cells targeting CD116/CD131 complexes exhibit enhanced anti‐tumor effects against acute myeloid leukaemia. Clinical & Translational Immunology. 10(5). e1282–e1282. 21 indexed citations
2.
Ohnota, Hideki, et al.. (2020). Skeletal muscle cells derived from mouse skin cultures. Biochemical and Biophysical Research Communications. 528(2). 398–403. 3 indexed citations
3.
Sasayama, Daimei, Nobuhiro Sugiyama, Shigeru Yonekubo, et al.. (2017). Novel oestrogen receptor β-selective ligand reduces obesity and depressive-like behaviour in ovariectomized mice. Scientific Reports. 7(1). 4663–4663. 23 indexed citations
4.
Nakamura, Tetsuya, Norihiko Kikuchi, Tomonaga Ozawa, et al.. (2012). Design, synthesis, and structure–activity relationship (SAR) of N-[7-(4-hydroxyphenoxy)-6-methylindan-4-yl]malonamic acids as thyroid hormone receptor β (TRβ) selective agonists. Bioorganic & Medicinal Chemistry. 21(3). 592–607. 5 indexed citations
5.
Mukaiyama, Harunobu, Hiroaki Kobayashi, Keiji Miyazawa, et al.. (2008). Structure–activity relationship studies of 5-benzylaminoimidazo[1,2-c]pyrimidine-8-carboxamide derivatives as potent, highly selective ZAP-70 kinase inhibitors. Bioorganic & Medicinal Chemistry. 17(1). 284–294. 20 indexed citations
6.
Mukaiyama, Harunobu, Hiroaki Kobayashi, Eiichi Tsuji, et al.. (2008). Structure–activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors. Bioorganic & Medicinal Chemistry. 16(20). 9247–9260. 26 indexed citations
7.
Mukaiyama, Harunobu, Hiroaki Kobayashi, Keiji Miyazawa, et al.. (2008). A novel Syk family kinase inhibitor: Design, synthesis, and structure–activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives. Bioorganic & Medicinal Chemistry. 16(15). 7347–7357. 33 indexed citations
8.
Mukaiyama, Harunobu, Satoko Kobayashi, Yoshimitsu Komatsu, et al.. (2007). Novel pyrazolo[1,5-a]pyrimidines as c-Src kinase inhibitors that reduce IKr channel blockade. Bioorganic & Medicinal Chemistry. 16(2). 909–921. 35 indexed citations
9.
Mukaiyama, Harunobu, Satoko Kobayashi, Yoshimitsu Komatsu, et al.. (2007). Discovery of Novel 2-Anilinopyrazolo[1,5-a]pyrimidine Derivatives as c-Src Kinase Inhibitors for the Treatment of Acute Ischemic Stroke. Chemical and Pharmaceutical Bulletin. 55(6). 881–889. 27 indexed citations
10.
11.
Komatsu, Hirotsugu, Hideki Ohnota, Tatsuya Koizumi, & Fumitoshi Satoh. (1997). [A rapid- and short-acting insulinotropic agent KAD-1229].. PubMed. 55 Suppl. 171–9. 1 indexed citations
12.
Ohnota, Hideki, et al.. (1996). Effect of a non‐sulphonylurea hypoglycaemic agent, KAD‐1229 on hormone secretion in the isolated perfused pancreas of the rat. British Journal of Pharmacology. 117(8). 1702–1706. 14 indexed citations
13.
Aizawa, Toru, Yasuo Terauchi, Naomi Suzuki, et al.. (1996). Analysis of the Pancreatic β Cell in the Mouse with Targeted Disruption of the Pancreatic β Cell-Specific Glucokinase Gene. Biochemical and Biophysical Research Communications. 229(2). 460–465. 17 indexed citations
14.
15.
Ohnota, Hideki, Takashi Koizumi, Miho Kobayashi, Fumiyasu Sato, & Yasunori Momose. (1995). Normalization of impaired glucose tolerance by the short-acting hypoglycemic agent calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate (KAD-1229) in non-insulin-dependent diabetes mellitus rats. Canadian Journal of Physiology and Pharmacology. 73(1). 1–6. 13 indexed citations
16.
17.
18.
Mogami, Hideo, et al.. (1994). Inhibition of ATP-sensitive K+ channel by a non-sulfonylurea compound KAD-1229 in a pancreatic β-cell line, MIN 6 cell. European Journal of Pharmacology Molecular Pharmacology. 269(3). 293–298. 32 indexed citations
19.
Okano, Masaki, Hideki Ohnota, & Ryuzo Sasaki. (1992). Protein Deficiency Impairs Erythropoiesis in Rats by Reducing Serum Erythropoietin Concentration and the Population Size of Erythroid Precursor Cells. Journal of Nutrition. 122(7). 1376–1383. 20 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Osamu Asano Breakdown of academic impact, for papers by Nahed K. Ahmed Breakdown of academic impact, for papers by J. C. Mani Breakdown of academic impact, for papers by Van N. Michalek Breakdown of academic impact, for papers by Naonori Inoue Breakdown of academic impact, for papers by Katsuhiro Kawakami Breakdown of academic impact, for papers by Paola Finotti Breakdown of academic impact, for papers by Katharina R. Beck Breakdown of academic impact, for papers by Stephen Eisennagel Breakdown of academic impact, for papers by Mark Hilliard
Rankless by CCL
2026